MD An­der­son buys tech from Bel­licum; Tar­sus’ Ly­me dis­ease tri­al da­ta; Rigel takes Gavre­to

Plus, Oc­u­lar Ther­a­peu­tix’s pri­vate place­ment, Lim­maT­e­ch Bi­o­log­ics’ shigel­losis vac­cine da­ta and a col­lab­o­ra­tion be­tween Hox Ther­a­peu­tics and Ver­nalis.

MD An­der­son buys tech from Bel­licum: The Texas can­cer re­search in­sti­tu­tion said it has ac­quired “cer­tain as­sets” and IP from its Hous­ton neigh­bor, which last year start­ed a strate­gic re­view process. MD An­der­son will use the “safe­ty switch” tech in its cell ther­a­pies, and the can­cer cen­ter plans to ink non-ex­clu­sive li­cens­es with oth­er aca­d­e­m­ic groups and bio­phar­ma com­pa­nies so they can ac­cess it, as well. — Kyle LaHu­cik

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.